ijms-logo

Journal Browser

Journal Browser

Targeting MAPK in Human Diseases

Special Issue Editor


E-Mail Website
Guest Editor
Dipartimento di Scienze Biomediche, Sperimentali e Cliniche, University of Florence, Florence, Italy
Interests: MAPK; targeted therapy; cancer; ERK5; cell signaling
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Mitogen-activated protein kinases (MAPKs) are serine–threonine protein kinases that play crucial roles in various biological processes, including cell proliferation, differentiation, apoptosis or survival, inflammation, and immunity. In mammals, the canonical MAPKs include c-Jun N-terminal kinases (JNK1/2/3), p38 MAPKs (which consist of the p38α, p38β, p38γ, and p38δ isoforms), and extracellular signal-regulated kinases (ERK1/2/5). Additionally, atypical MAPKs such as ERK3/4, ERK7/8, and Nemo-like kinase (NLK) have been identified. Together, these MAPKs regulate numerous substrates, including members of a family of Ser/Thr protein kinases known as MAPK-activated protein kinases (MAPKAPKs). Dysregulation of MAPK pathways is associated with a variety of diseases, including cancer, chronic inflammatory conditions, and neurodegenerative disorders. Among the many factors involved in regulating the duration, magnitude, and spatiotemporal profiles of MAPK activity, dual-specificity phosphatases (DUSPs) play a crucial role by dephosphorylating key signaling molecules, including MAPKs.

This Special Issue aims to emphasize the role of MAPKs in human diseases and explore strategies for targeting these pathways to mitigate the impact of their deregulation on human health.

Dr. Elisabetta Rovida
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ERK
  • DUSP
  • cancer
  • inflammation
  • neurodegenerative diseases
  • autoimmune diseases
  • targeted therapy
  • cell signaling

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

29 pages, 1295 KB  
Review
Dual-Specificity Protein Phosphatases Targeting Extracellular Signal-Regulated Kinases: Friends or Foes in the Biology of Cancer?
by Alessandro Tubita, Dimitri Papini, Ignazia Tusa and Elisabetta Rovida
Int. J. Mol. Sci. 2025, 26(17), 8342; https://doi.org/10.3390/ijms26178342 - 28 Aug 2025
Viewed by 1465
Abstract
Dual-specificity protein phosphatases (DUSPs) are a family of proteins that dephosphorylate both phospho-serine/threonine and phospho-tyrosine residues of Mitogen-Activated Protein Kinases (MAPKs). MAPKs are involved in a large number of cellular processes, including proliferation, differentiation, apoptosis, and stress responses. Therefore, dysregulation or improper functioning [...] Read more.
Dual-specificity protein phosphatases (DUSPs) are a family of proteins that dephosphorylate both phospho-serine/threonine and phospho-tyrosine residues of Mitogen-Activated Protein Kinases (MAPKs). MAPKs are involved in a large number of cellular processes, including proliferation, differentiation, apoptosis, and stress responses. Therefore, dysregulation or improper functioning of the MAPK signalling is involved in the onset and progression of several diseases, including cancer. Likewise, dysregulation of DUSPs markedly affects cancer biology. The importance of MAPKs in the modulation of tumour development has been known for a long time, and MAPKs are consistently used as molecular targets for cancer therapy. However, in the last decade, DUSPs have acquired a greater interest as possible therapeutic targets to regulate MAPK activity and to prevent resistance mechanisms to MAPK-targeting therapies. Moreover, the possibility of exploiting DUSPs as biomarkers for the diagnosis and prognosis of specific types of cancer is also emerging. In this review, we report what is known in the literature on the role of DUSPs in cancer onset and progression, focusing on those targeting the extracellular signal-regulated kinases (ERKs), in particular ERK1/2 and ERK5 conventional MAPKs. The specific role of each ERK-targeting DUSP in supporting or hampering cancer progression in the context of different types of cancer is also discussed. Full article
(This article belongs to the Special Issue Targeting MAPK in Human Diseases)
Show Figures

Figure 1

Back to TopTop